

October 29, 2019



Interpace to Present Data at the ATA Annual Meeting

PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual Meeting of the American Thyroid Association (ATA), being held October 30th to November 3rd, 2019 in Chicago, IL. The ATA meeting is one of the largest gatherings of endocrinologists, ENT's, surgeons and other providers who focus on the diagnosis and treatment of thyroid cancer.

Interpace will be presenting three separate posters focused on the performance of the company's molecular tests for indeterminate thyroid nodules, ThyGeNEXT[®] and ThyraMIR[®], and are titled:

- "Estimation of malignancy association for mutations and fusions, detected by NGS, by incorporating the results of microRNA expression profiling assay for a large set of clinical specimens"
- "Molecular analysis of non-Diagnostic (B-I) thyroid nodule cytology samples using combined mutational detection and microRNA classifier test"
- "Molecular diagnosis of medullary thyroid carcinoma by NGS mutation detection and microRNA expression profiling"

Together these posters underline the clinical utility of ThyGeNEXT[®] and ThyraMIR[®] in assessing the risk of thyroid nodules with indeterminate cytology results progressing to cancer. They also highlight progress made by the Company to provide quality diagnostic information for the detection of aggressive forms of thyroid cancer.

Jack Stover, CEO of Interpace, stated, "We are pleased that our data has been accepted for presentation in this prestigious forum and look forward to sharing our work with such an established group of attendees." Mr. Stover continued, "The acceptance of our data supports our belief that our molecular products continue to add value to physicians and patients at risk of thyroid cancer."

About Thyroid Nodules, ThyGeNEXT[®] and ThyraMIR[®] Testing

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT[®] and ThyraMIR[®].

ThyGeNEXT[®] and ThyraMIR[®] reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can

improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

ThyGeNEXT[®] utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR[®] is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR[®] measures the expression of 10 microRNAs. Both ThyGeNEXT[®] and ThyraMIR[®] are covered by both Medicare and Commercial insurers, with more than 280 million patients covered.

About Interpace

Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace's Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN[®] for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT[®] for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR[®] for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX[®] that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN[®] for Barrett's Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN[®] to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpace's Biopharma Business provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace's website at www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans,"

"projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to the fact that there is no assurance the acquisition of the BioPharma business of Cancer Genetics, Inc. will be successfully integrated with the Company, or that the potential benefits of the acquisition, including future revenues, will be successfully realized. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 10-K, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Investor Relations - Edison Group

Joseph Green

(646) 653-7030

jgreen@edisongroup.com



Source: Interpace Diagnostics Group, Inc.